A Multicenter Phase II Trial of Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
Latest Information Update: 06 Sep 2024
At a glance
- Drugs Sintilimab (Primary) ; Bevacizumab; Carboplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms NIBCUN
- 04 Sep 2024 Planned End Date changed from 1 Mar 2024 to 1 Dec 2026.
- 04 Sep 2024 Planned primary completion date changed from 1 Mar 2021 to 1 Dec 2025.
- 14 Apr 2019 Planned number of patients changed from 37 to 36.